Follitropin delta medicines open-house rebate agreements

Summary

The tender concerns an open-house framework for rebate agreements for the active substance follitropin delta. Techniker Krankenkasse intends to conclude uniform contracts with all suitable pharmaceutical companies; there are no individual negotiations and no exclusivity. The contract term is up to 24 months from 1 June 2025 and ends no later than 31 May 2027, with automatic early termination if the patent or market exclusivity expires earlier. Participation is possible at any time during the contract term, but participation and contract documents are only provided to companies that market, or can credibly demonstrate an intention to market, medicines containing the relevant active substance.